Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
| 01-2023 | 12-2022 | 10-2022 | 09-2022 | 07-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,418 | N/A | -24,462 | -589 | N/A |
| Depreciation Amortization | 46 | N/A | 238 | N/A | 0 |
| Accounts payable and accrued liabilities | 827 | N/A | -197 | N/A | N/A |
| Other Working Capital | -1,442 | N/A | 2,174 | 727 | 522 |
| Other Operating Activity | 1,764 | 0 | 4,655 | -750 | -155 |
| Operating Cash Flow | $-6,223 | $N/A | $-17,592 | $-612 | $368 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | N/A | -153 | N/A | 0 |
| Investing Cash Flow | $-13 | $N/A | $-153 | $N/A | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 18,400 | N/A | N/A |
| Debt Issued | N/A | N/A | 11,000 | N/A | N/A |
| Debt Repayment | N/A | N/A | -1,010 | N/A | N/A |
| Common Stock Issued | N/A | N/A | 12 | N/A | N/A |
| Other Financing Activity | -10 | 0 | -435 | 0 | 0 |
| Financing Cash Flow | $-10 | $N/A | $27,967 | $N/A | $0 |
| Exchange Rate Effect | 1 | N/A | -805 | N/A | 0 |
| Beginning Cash Position | 20,434 | N/A | 11,017 | 1,069 | N/A |
| End Cash Position | 14,189 | N/A | 20,434 | 457 | N/A |
| Net Cash Flow | $-6,245 | $N/A | $9,417 | $-612 | $368 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,223 | N/A | -17,592 | -612 | 368 |
| Capital Expenditure | -13 | N/A | -153 | N/A | N/A |
| Free Cash Flow | -6,236 | 0 | -17,745 | -612 | 368 |